Aurora Deutschland

What Aurora Deutschland does

Aurora Deutschland GmbH is a Berlin-headquartered pharmaceutical company and wholly-owned subsidiary of Aurora Cannabis Inc. (TSX: ACB) that manufactures and distributes medical cannabis exclusively to licensed pharmacies in Germany. The company sells pharmaceutical-grade dried flower, cannabis extracts and oils, and inhalable extracts/resin cartridges through five distinct brands (Aurora Medical, Pedanios, IndiMed, Daily Special, San Raf) targeting different patient needs and price points.

Vertically integrated operations span genetics research at Aurora Coast in British Columbia (over 18,000 sq ft of greenhouse R&D testing nearly 10,000 unique genotypes annually, with over 20 exclusive cultivars licensed to third parties), cultivation and manufacturing at the EU-GMP certified Aurora Leuna facility in Sachsen-Anhalt (one of only three licensed cannabis cultivation sites in Germany under both the 2019 BfArM tender and 2024 Medical Cannabis Act licenses), and direct B2B distribution to German, Polish, UK, and French (via Ethypharm) pharmacies.

Aurora generates revenue through three primary streams: (1) per-order wholesale sales of medical cannabis products to pharmacies (dried flower, extracts, oils, inhalable extracts) via online shop, fax, email, and Key Account Managers; (2) genetics licensing royalties and upfront fees on its proprietary cannabis cultivar portfolio; and (3) bulk supply agreements to pharmaceutical distributors such as Ethypharm for the French Pilot Program. Order terms are 14-day net with statutory late-payment interest. The go-to-market is field-led enterprise sales supported by a comprehensive healthcare-professional engagement layer (DocCheck-gated portal, Aurora Hotline, Aurora Academy, Copeia Physicians Experience Platform, 13+ telemedicine referral partnerships), positioning the company for sustained growth on the back of Germany's 2024 Medical Cannabis Act and continued European rollout.

Name

Aurora Deutschland

Legal name

Aurora Deutschland GmbH

Website

https://auroramedicine.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Aurora Deutschland GmbH, a wholly-owned subsidiary of Aurora Cannabis Inc. (TSX: ACB), manufactures and distributes EU-GMP certified medical cannabis (dried flower, extracts, oils, inhalable extracts) under five brands to licensed pharmacies across Germany, Poland, France, and the UK, leveraging one of only three German cultivation licenses and an integrated genetics-to-pharmacy supply chain.

Ownership category

akta.pro rank

Product category

Pharmaceutical Cannabis Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industry

Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)

Keywords

• Medical cannabis manufacturing
• Pharmaceutical cannabis distribution
• EU-GMP cannabis production
• Cannabis genetics licensing
• Pharmacy cannabis wholesale

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Medical Cannabis Product Sales (Pharmacy Channel): Aurora sells pharmaceutical-grade medical cannabis products (dried flower, extracts, oils, inhalable extracts) exclusively to pharmacies in legally regulated markets. Products are sold via direct sales, fax, email, and online shop. This is the primary revenue stream, with pricing set per product/order and sales conducted in commercial quantities to pharmacy buyers.
2. Genetics Licensing: Aurora licenses its proprietary cannabis genetics to third-party cultivators and producers. Over 20 exclusive cultivars are available for trial and licensing. Licensing generates royalties and upfront fees from partners seeking access to Aurora's premium genetics portfolio.
3. French Pilot Program Supply (via Ethypharm): In partnership with Ethypharm, Aurora became the sole supplier of medical cannabis dried flower for the French Pilot Program, generating revenue from bulk supply agreements with a pharmaceutical distribution partner.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Aurora Deutschland is a vertically integrated pharmaceutical-grade medical cannabis manufacturer and wholesale distributor that cultivates, processes, and supplies cannabis-based medicines (dried flower, extracts/oils, and inhalable resin cartridges) to licensed pharmacies across Germany, Poland, France, and the UK. Products are sold under five distinct brands — Aurora Medical, Pedanios, IndiMed, Daily Special, and San Raf — with production anchored at the EU-GMP certified Aurora Leuna facility in Germany, and the company also licenses its proprietary cannabis genetics to third parties.

Product overview

Aurora is a vertically integrated medical cannabis company managing the entire value chain from genetics research to product development, cultivation, and manufacturing. The company operates EU-GMP certified facilities in Canada and Germany (Leuna facility, one of only three licensed cultivation sites in Germany). Aurora's product portfolio comprises multiple brands including Aurora Medical (core comprehensive portfolio), Pedanios (pioneering German market brand with flower and full-spectrum extracts), IndiMed (personalized care focus), Daily Special (high-value accessibility), and San Raf (high-THC discovery-focused). Product types include medical cannabis dried flower, extracts/oils, and inhalable extracts/resin cartridges. The company serves patients across legally regulated European markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Aurora Medical Core Aurora Medical brand offering a comprehensive portfolio of pharmaceutical-grade medical cannabis products (flower, extracts, oils, inhalable extracts) developed with focus on quality, consistency and reliability, sold via direct supply to pharmacies across Europe.
• Pedanios Pioneering medical cannabis brand in the German market offering dried cannabis flower and full-spectrum extracts suited to a range of patient needs, supplied to licensed German pharmacies.
• IndiMed (German-cultivated medical cannabis products) IndiMed brand medical cannabis products designed to support personalised care and improve patient access at value-oriented price points; in 2025 expanded to include first German-cultivated IndiMed products following EU-GMP certification of the Aurora Leuna facility.
• Daily Special Value-oriented medical cannabis brand committed to making pharmaceutical-grade cannabis more accessible through high-value products aimed at lowering cost barriers for patients.
• San Raf Discovery-oriented medical cannabis brand offering top-quality high-THC products available in a wide variety of strains and formats, targeted at patients seeking potent therapeutic options.
• Medical Cannabis Dried Flower Pharmaceutical-grade dried cannabis flower cultivated at Aurora Leuna (Germany) under EU-GMP and GACP standards, hand-harvested, hang-dried, hand-trimmed, and lab-tested for purity and active ingredient content; supplied to licensed pharmacies.
• Cannabis Extracts and Oils Pharmaceutical-grade cannabis extracts and oils designed to support precise, consistent dosing and offer flexible treatment options for patients, with accurate administration and ease of use.
• Inhalable Extracts (Resin Cartridges) High-potency inhalable resin cartridge extracts using high-quality terpenes to deliver rich flavours with controllable, consistent consumption in a portable and discreet format.

Quantifiable outcome

• One of only three licensed cultivation sites in Germany, with BfArM tender secured in 2019 and additional licenses in 2024
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• EthypharmcoreChannel Partner/ Reseller/ Distributor · 1 January 2021In partnership with Ethypharm, Aurora became the sole supplier of medical cannabis dried flower for the French Pilot Program (2021), with Ethypharm distributing Aurora's products in France.
• Humboldt University of BerlincoreStrategic or Co-development Partner · 1 January 2019In 2019, Aurora initiated Europe's first interdisciplinary academic cannabis research class with Humboldt University of Berlin, advancing medical cannabis education and research in Europe.
• BvCW (Bundesverband Cannabiswirtschaft / Cannabis Industry Association)coreGTM or Marketing PartnerThe Cannabis Industry Association (BvCW) is the central trade association representing the interests of the German cannabis sector. Aurora collaborates with the BvCW by contributing expertise in medical cannabis policy to help shape the regulatory framework.
• BPC (Bundesverband pharmazeutischer Cannabinoidunternehmen / Federal Association of Pharmaceutical Cannabinoid Companies)coreStrategic or Co-development PartnerBPC specializes in medical cannabis in Germany. Aurora is involved on the board of directors and is active in working groups, policy, research, and external communications initiatives.
• VCA (Verband der Cannabis versorgenden Apotheken e.V. / Association of Cannabis-Supplying Pharmacies)coreGTM or Marketing PartnerVCA represents pharmacies that supply medical cannabis, ensuring efficient and affordable patient access. Through this partnership, Aurora supports the development of quality and regulatory standards.
• Copeia — Physicians Experience Platform (PEP)coreStrategic or Co-development PartnerDeveloped in partnership with Aurora, the Physicians Experience Platform (PEP) aims to enhance personalized therapy with cannabis medications. PEP provides medical professionals with easy and free access to a platform that visually presents medical experiences through structured case studies.
• IG Hanf (Interest Group Hemp, Switzerland)minorGTM or Marketing PartnerAs the leading cannabis association in Switzerland, IG Hemp represents the Swiss hemp industry. The partnership contributes expertise to emphasize healthy and sustainable industry regulations in the region.
• CIC (Cannabis Industry Council, UK)coreGTM or Marketing PartnerThe CIC defines, sets, and maintains the highest standards for operational excellence in the UK medical cannabis sector. Aurora UK participates on the CIC Executive Council, working to shape the future of cannabis in the UK.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Canopy Growth Corporation: Canopy Growth supplies medical cannabis across Europe through its Storz & Bickel and Spectrum Therapeutics brands. Its pharmaceutical-grade cannabis flower, oils, and pharmacy-distribution model are directly comparable to Aurora Deutschland's EU-GMP offering.
• Cannamedical Pharma: Cannamedical is a German medical-cannabis wholesale distributor that imports and supplies flower and extracts to German pharmacies. It competes directly with Aurora Deutschland for pharmacy-channel share in Germany.
• DEMECAN: DEMECAN is the other German-domestic cannabis cultivator (one of the three BfArM-licensed sites). It directly competes with Aurora Deutschland in German-grown medical cannabis flower, cultivation licensing, and pharmacy supply.
• Tilray Brands: Tilray distributes medical cannabis — including the 2024 German "Cannabis" Tilray whole-flower brand — to German pharmacies. It competes head-to-head with Aurora Deutschland's flower, extract, and pharmacy-channel offerings in Germany and other European markets.

Others

• Ethypharm: Ethypharm is Aurora's distribution partner for the French Pilot Program. While not strictly a competitor, its pharmaceutical-distribution infrastructure is comparable to the type of channel Aurora relies on, and Ethypharm could elect to source from other cultivators over time.

Broad incumbents

• STADA Arzneimittel AG: STADA is a major German specialty pharmaceutical company with growing activity in medical cannabis through partnerships and distribution. Its pharmacy-channel footprint and EU-GMP heritage make it a broad incumbent comparable to Aurora Deutschland's go-to-market.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz Pharmaceuticals operates GW's cannabinoid-based pharmaceutical portfolio (Sativex, Epidiolex), representing a large incumbent in plant-derived cannabinoid therapeutics. Aurora Deutschland's EU-GMP, physician-targeted medical cannabis model sits adjacent to these prescription cannabinoid products.

Emerging players

• Cantourage GmbH: Cantourage partners with international cannabis producers (including some smaller EU cultivators) and supplies German pharmacies with medical cannabis extracts and flower. It overlaps with Aurora Deutschland in pharmacy-channel medical cannabis distribution in Germany.
• OrganiGram Holdings: OrganiGram is a Canadian licensed producer with European medical-cannabis ambitions. Its cannabis cultivation, EU-export footprint, and pharmaceutical-grade product positioning make it a comparable emerging competitor to Aurora Deutschland.
• Four 20 Pharma GmbH: Four 20 Pharma is a German medical-cannabis supplier distributing flower, oils, and extracts to German pharmacies. It directly overlaps with Aurora Deutschland in pharmacy-channel flower and extract supply in Germany.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/aurora_mmj/?lang=en
• LinkedInlinkedin.com/company/aurora-cannabis-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurora Deutschland